![Inhibikase Therapeutics Inc Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/ikt.png?tr=w-200)
Inhibikase Therapeutics Inc
NASDAQ:IKT
![Inhibikase Therapeutics Inc Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/ikt.png)
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Realty Income Corp
NYSE:O
|
Real Estate
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
US |
![]() |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/ikt.png)
Inhibikase Therapeutics Inc
Net Issuance of Common Stock
Inhibikase Therapeutics Inc
Net Issuance of Common Stock Peer Comparison
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nyse/abbv.png)
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/gild.png)
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/amgn.png)
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/vrtx.png)
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/regn.png)
Competitive Net Issuance of Common Stock Analysis
Latest Figures & CAGR of Competitors
Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
![]() |
Inhibikase Therapeutics Inc
NASDAQ:IKT
|
Net Issuance of Common Stock
$361.2k
|
CAGR 3-Years
-71%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
![]() |
Abbvie Inc
NYSE:ABBV
|
Net Issuance of Common Stock
-$1.1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
37%
|
CAGR 10-Years
-18%
|
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
Net Issuance of Common Stock
-$719m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
22%
|
CAGR 10-Years
-2%
|
![]() |
Amgen Inc
NASDAQ:AMGN
|
Net Issuance of Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Issuance of Common Stock
-$288.7m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Issuance of Common Stock
-$473.2m
|
CAGR 3-Years
51%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Inhibikase Therapeutics Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
361.2k
USD
Based on the financial report for Mar 31, 2024, Inhibikase Therapeutics Inc's Net Issuance of Common Stock amounts to 361.2k USD.
What is Inhibikase Therapeutics Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
-21%
Over the last year, the Net Issuance of Common Stock growth was -96%. The average annual Net Issuance of Common Stock growth rates for Inhibikase Therapeutics Inc have been -71% over the past three years , -21% over the past five years .